Table 2.
Tumor response according to RECIST version 1.1 (response-evaluable population)
| Response | Patients, n (%) | P a | |||
|---|---|---|---|---|---|
| All patients (N = 64) | Cohort 1 (n = 22) | Cohort 2 (n = 19) | Cohort 3 (n = 23) | ||
| CR | 0 | 0 | 0 | 0 | NA |
| PR | 42 (66) | 15 (68) | 12 (63) | 15 (65) | 0.94 |
| SD | 15 (23) | 5 (23) | 4 (21) | 6 (26) | 0.93 |
| PD | 7 (11) | 2 (9) | 3 (16) | 2 (9) | 0.72 |
| ORR | 42 (66) | 15 (68) | 12 (63) | 15 (65) | 0.94 |
| DCR | 57 (89) | 20 (91) | 16 (84) | 21 (91) | 0.72 |
Cohort 1, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 260 mg/m2 day 1 Q3W; Cohort 2, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 140 mg/m2 day 1, 8 Q3W; Cohort 3, cisplatin 75 mg/m2 day 1 + nab-paclitaxel 100 mg/m2 day 1, 8, 15 Q3W
a P value for the inter-cohort difference
NA, not applicable; PD, progressive disease